secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0001193125-23-268185
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara Biotherapeutics establishes $100M ATM equity facility with TD Cowen
-------------------------------------------------------------------------

- Entered into an at-the-market (ATM) sales agreement with TD Cowen for up to $100M in common stock.
- Commission of up to 3.0% on gross proceeds; company controls timing and size of sales.
- Replaces existing 2021 ATM facility once new shelf registration statement becomes effective.
- No sales permitted until the registration statement is declared effective by the SEC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312523268185/0001193125-23-268185-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312523268185/d527002d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-268185

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer